JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Crinetics Pharmaceuticals (CRNX) and maintained a $60 price target.
March 13, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirms a Market Outperform rating and a $60 price target for Crinetics Pharmaceuticals.
The reiteration of a Market Outperform rating and a maintained price target of $60 by a reputable analyst suggests a strong confidence in Crinetics Pharmaceuticals' future performance. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in CRNX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100